Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Aytu Biopharma (AYTU) over the last 17 years, with Jun 2025 value amounting to 11.79%.

  • Aytu Biopharma's EBITDA Margin fell 522.00% to 10.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.19%, marking a year-over-year decrease of 968.00%. This contributed to the annual value of 11.79% for FY2025, which is 845.00% down from last year.
  • Aytu Biopharma's EBITDA Margin amounted to 11.79% in FY2025, which was down 252.71% from 3.34% recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's EBITDA Margin ranged from a high of 3.34% in FY2024 and a low of 113.69% during FY2022.
  • In the last 3 years, Aytu Biopharma's EBITDA Margin had a median value of 11.79% in 2025 and averaged 10.34%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by 2,400bps in 2022, then skyrocketed by 9,780bps in 2023.
  • MRY analysis of 5 years shows Aytu Biopharma's EBITDA Margin stood at 89.70% in 2021, then fell by 27bps to 113.69% in 2022, then soared by 86bps to 15.89% in 2023, then surged by 79bps to 3.34% in 2024, then plummeted by 253bps to 11.79% in 2025.
  • Its EBITDA Margin stands at 11.79% for FY2025, versus 3.34% for FY2024 and 15.89% for FY2023.